浙江省11家医院2010—2015年双膦酸盐类药物治疗乳腺癌骨转移相关骨损害及疼痛的利用研究(4)
[ 2 ] LIU J， HUANG W， ZHOU R， et al. Bisphosphonates in the treatment of patients with metastatic breast， lung， and prostate cancer： a meta-analysis[J]. Medicine ：Baltimore， 2015， 94(46)：e2014.
[ 3 ] MATHEW A，BRUFSKY A. Bisphosphonates in breast cancer[J]. Int J Cancer， 2015， 137(4)：753-764.
[ 4 ] ERDOGAN B， CICIN I. Medical treatment of breast cancer bone metastasis： from bisphosphonates to targeted drugs[J]. Asian Pac J Cancer Prev，2014，15(4)：1503- 1510.
[ 5 ] PATEL S，LYONS AR，HOSKING DJ.Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use[J]. Drugs，1993， 46(4)：594-617.
[ 6 ] ROSA MENDOZA ES， MORENO E， CAGUIOA PB. Predictors of early distant metastasis in women with breast cancer[J]. J Cancer Res Clin Oncol， 2013，139(4)：645-652.
[ 7 ] Early Breast Cancer Trialists， Collaborative Group(EB- CTCG). Adjuvant bisphosphonate treatment in early breast cancer： meta-analyses of individual patient data from randomised trials[J]. Lancet， 2015，386(10001)：1353-1361.
[ 8 ] CLEELAND CS， BODY JJ， STOPECK A，et al. Pain outcomes in patients with advanced breast cancer and bone metastases： results from a randomized， double-blind study of denosumab and zoledronic acid[J]. Cancer， 2013，119(4)：832-838.
[ 9 ] VALACHIS A，POLYZOS NP，COLEMAN RE， et al. Adjuvant therapy with zoledronic acid in patients with breast cancer：a systematic review and meta-analysis[J]. Oncologist，2013，18(4)：353-361.
[10] MORGAN GJ， DAVIES FE， GREGORY WM， et al. Long-term follow-up of MRC Myeloma IX trial： survival outcomes with bisphosphonate and thalidomide treatment[J]. Clin Cancer Res， 2013， 19(21)：6030-6038.
[11] 朱志偉，肖楠，方翎. 国产进口唑来膦酸治疗恶性肿瘤骨转移抑痛等效果成本比较[J].浙江临床医学， 2009，11(4)：368-370.
[12] 曹桂侠，程朝辉，周冬梅.唑来膦酸与帕米膦酸二钠治疗恶性肿瘤骨转移性疼痛比较分析[J]. 肿瘤基础与临床， 2013， 26(1) 59-61.
[13] MAJOR P， LORTHOLARY A， HON J， et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy： a pooled analysis of two randomized， controlled clinical trials[J]. J Clin Oncol，2001，19(2)：558-567.
(收稿日期：2017-04-30 修回日期：2018-03-07)
(编辑：周 箐), 百拇医药(曹莹莹 王增 方罗 戚雅君 余佳文 骆虹 宋俞)
[ 3 ] MATHEW A，BRUFSKY A. Bisphosphonates in breast cancer[J]. Int J Cancer， 2015， 137(4)：753-764.
[ 4 ] ERDOGAN B， CICIN I. Medical treatment of breast cancer bone metastasis： from bisphosphonates to targeted drugs[J]. Asian Pac J Cancer Prev，2014，15(4)：1503- 1510.
[ 5 ] PATEL S，LYONS AR，HOSKING DJ.Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use[J]. Drugs，1993， 46(4)：594-617.
[ 6 ] ROSA MENDOZA ES， MORENO E， CAGUIOA PB. Predictors of early distant metastasis in women with breast cancer[J]. J Cancer Res Clin Oncol， 2013，139(4)：645-652.
[ 7 ] Early Breast Cancer Trialists， Collaborative Group(EB- CTCG). Adjuvant bisphosphonate treatment in early breast cancer： meta-analyses of individual patient data from randomised trials[J]. Lancet， 2015，386(10001)：1353-1361.
[ 8 ] CLEELAND CS， BODY JJ， STOPECK A，et al. Pain outcomes in patients with advanced breast cancer and bone metastases： results from a randomized， double-blind study of denosumab and zoledronic acid[J]. Cancer， 2013，119(4)：832-838.
[ 9 ] VALACHIS A，POLYZOS NP，COLEMAN RE， et al. Adjuvant therapy with zoledronic acid in patients with breast cancer：a systematic review and meta-analysis[J]. Oncologist，2013，18(4)：353-361.
[10] MORGAN GJ， DAVIES FE， GREGORY WM， et al. Long-term follow-up of MRC Myeloma IX trial： survival outcomes with bisphosphonate and thalidomide treatment[J]. Clin Cancer Res， 2013， 19(21)：6030-6038.
[11] 朱志偉，肖楠，方翎. 国产进口唑来膦酸治疗恶性肿瘤骨转移抑痛等效果成本比较[J].浙江临床医学， 2009，11(4)：368-370.
[12] 曹桂侠，程朝辉，周冬梅.唑来膦酸与帕米膦酸二钠治疗恶性肿瘤骨转移性疼痛比较分析[J]. 肿瘤基础与临床， 2013， 26(1) 59-61.
[13] MAJOR P， LORTHOLARY A， HON J， et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy： a pooled analysis of two randomized， controlled clinical trials[J]. J Clin Oncol，2001，19(2)：558-567.
(收稿日期：2017-04-30 修回日期：2018-03-07)
(编辑：周 箐), 百拇医药(曹莹莹 王增 方罗 戚雅君 余佳文 骆虹 宋俞)